Expand RGNX Menu
RGNX MENU

RGNX Latest Press Releases

-- February 9, 2026 --

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II PRNewswire 4:05 PM

-- February 3, 2026 --

RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm Business Wire 3:06 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX Globe Newswire 1:57 PM

-- January 29, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of REGENXBIO Inc. - RGNX PRNewswire 7:01 PM
Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action PRNewswire 6:06 PM

-- January 28, 2026 --

INVESTOR ALERT: Investigation of REGENXBIO Inc. (RGNX) by Holzer & Holzer, LLC Globe Newswire 2:16 PM
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs PRNewswire 7:30 AM

-- January 11, 2026 --

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program PRNewswire 3:00 PM

-- December 18, 2025 --

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference PRNewswire 7:05 AM

-- November 25, 2025 --

REGENXBIO to Participate in Upcoming Investor Conference PRNewswire 7:05 AM

-- November 6, 2025 --

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights PRNewswire 7:05 AM

-- October 30, 2025 --

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program PRNewswire 7:05 AM

-- October 29, 2025 --

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights PRNewswire 7:05 AM

-- October 15, 2025 --

REGENXBIO to Participate in Upcoming Investor Conferences PRNewswire 7:05 AM

-- October 9, 2025 --

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting PRNewswire 7:05 AM

-- October 6, 2025 --

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD PRNewswire 7:05 AM

-- September 29, 2025 --

REGENXBIO Announces Presentation at the World Muscle Society PRNewswire 7:05 AM
Market Data Delayed 15 Minutes